MVMD Is Now The More Life Company™
Read the announcementViewWe help biology perform better. Across agriculture and human health, our technologies address practical constraints that can limit crop productivity, molecule formulation and effective delivery.
Agriculture
Biological plant-signaling technology designed to support crop productivity, resilience and more efficient use of available inputs.
For growers, distributors and agricultural partners seeking measurable performance under real-world growing conditions.
Explore Agrarius™Human Health
Sublingual formulation and delivery technology for selected molecules limited by oral degradation, inconsistent absorption, injection or cold-chain requirements.
Solubility formulation technology for selected molecules limited by poor aqueous solubility.
For formulators, compound pharmacies, manufacturers and commercial partners seeking differentiated delivery and formulation solutions.
Explore Human Health
Press releases, company updates and coverage from across our human health and agriculture platforms.
The More Life Company (formerly MVMD), announces the completion of its corporate name change and is pleased to announce that its common shares will continue to be quoted on the OTCID under the new trading symbol “TMLCF”.
The More Life Company, formerly Mountain Valley MD Holdings Inc. (CSE: MVMD) (OTC: MVMDF), is pleased to announce that it has completed a corporate name change.
This morning, we announced the completion of our corporate name change from Mountain Valley MD to The More Life Company.
The Company has appointed the five individuals listed below as advisors to provide strategic advisory services to the Company.
This morning we announced the appointment of five additional advisors to MVMD,
Mountain Valley MD advances QuickSome™ sublingual delivery platform for compounded peptide applications, reports on initial formulation work across multiple peptides including BPC-157
Quicksome™ Technology and the Emerging Peptide Opportunity
Under the terms of the Offering, the Company intends to issue up to 80,000,000 units at a price of CDN $0.025 per Unit.
MVMD enters 2026 positioned to convert validated progress across nutraceuticals, agriculture, and husbandry into disciplined, science-backed commercial growth through focused execution and responsible capital allocation.